S&P 500   5,033.81 (-0.35%)
DOW   37,821.45 (+0.06%)
QQQ   427.23 (-0.90%)
AAPL   168.66 (-0.43%)
MSFT   412.70 (-0.45%)
META   495.97 (-0.76%)
GOOGL   155.83 (+0.93%)
AMZN   181.40 (-1.05%)
TSLA   157.07 (-0.03%)
NVDA   852.03 (-2.53%)
AMD   155.61 (-4.80%)
NIO   3.95 (+3.67%)
BABA   69.11 (-0.72%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.31 (-3.66%)
GE   155.23 (-0.98%)
CGC   6.60 (-1.49%)
DIS   113.38 (-0.44%)
AMC   2.96 (+8.82%)
PFE   25.42 (-1.05%)
PYPL   63.27 (-0.25%)
XOM   118.52 (-0.14%)
S&P 500   5,033.81 (-0.35%)
DOW   37,821.45 (+0.06%)
QQQ   427.23 (-0.90%)
AAPL   168.66 (-0.43%)
MSFT   412.70 (-0.45%)
META   495.97 (-0.76%)
GOOGL   155.83 (+0.93%)
AMZN   181.40 (-1.05%)
TSLA   157.07 (-0.03%)
NVDA   852.03 (-2.53%)
AMD   155.61 (-4.80%)
NIO   3.95 (+3.67%)
BABA   69.11 (-0.72%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.31 (-3.66%)
GE   155.23 (-0.98%)
CGC   6.60 (-1.49%)
DIS   113.38 (-0.44%)
AMC   2.96 (+8.82%)
PFE   25.42 (-1.05%)
PYPL   63.27 (-0.25%)
XOM   118.52 (-0.14%)
S&P 500   5,033.81 (-0.35%)
DOW   37,821.45 (+0.06%)
QQQ   427.23 (-0.90%)
AAPL   168.66 (-0.43%)
MSFT   412.70 (-0.45%)
META   495.97 (-0.76%)
GOOGL   155.83 (+0.93%)
AMZN   181.40 (-1.05%)
TSLA   157.07 (-0.03%)
NVDA   852.03 (-2.53%)
AMD   155.61 (-4.80%)
NIO   3.95 (+3.67%)
BABA   69.11 (-0.72%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.31 (-3.66%)
GE   155.23 (-0.98%)
CGC   6.60 (-1.49%)
DIS   113.38 (-0.44%)
AMC   2.96 (+8.82%)
PFE   25.42 (-1.05%)
PYPL   63.27 (-0.25%)
XOM   118.52 (-0.14%)
S&P 500   5,033.81 (-0.35%)
DOW   37,821.45 (+0.06%)
QQQ   427.23 (-0.90%)
AAPL   168.66 (-0.43%)
MSFT   412.70 (-0.45%)
META   495.97 (-0.76%)
GOOGL   155.83 (+0.93%)
AMZN   181.40 (-1.05%)
TSLA   157.07 (-0.03%)
NVDA   852.03 (-2.53%)
AMD   155.61 (-4.80%)
NIO   3.95 (+3.67%)
BABA   69.11 (-0.72%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.31 (-3.66%)
GE   155.23 (-0.98%)
CGC   6.60 (-1.49%)
DIS   113.38 (-0.44%)
AMC   2.96 (+8.82%)
PFE   25.42 (-1.05%)
PYPL   63.27 (-0.25%)
XOM   118.52 (-0.14%)
LON:REDX

Redx Pharma (REDX) Share Price, News & Analysis

GBX 13
+2.00 (+18.18%)
(As of 04:29 PM ET)
Today's Range
10.50
14.50
50-Day Range
4.25
24
52-Week Range
4
37.90
Volume
2.60 million shs
Average Volume
717,374 shs
Market Capitalization
£50.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
REDX stock logo

About Redx Pharma Stock (LON:REDX)

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

REDX Stock Price History

REDX Stock News Headlines

Redx Pharma PLC REDX
Top 5 AI Stocks to Buy for 2024
5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.
Redx Pharma Plc (LON:REDX) Insider Acquires £31,920 in Stock
Top 5 AI Stocks to Buy for 2024
5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.
Redx Pharma (LON:REDX) Sets New 52-Week Low at $4.00
Sterling ticks up as UK manufacturing recovers
Redx Pharma Says Not Involved in U.S.-Listing Process
Redx Pharma PLC 0RX
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
Redx Pharma seals $880m cancer research partnership
Redx Pharma Share Chat
See More Headlines
Receive REDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/19/2018
Today
4/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
101
Year Founded
N/A

Profitability

Net Income
£-33,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£4.20 million
Cash Flow
GBX 2.58 per share
Book Value
GBX 1 per share

Miscellaneous

Free Float
N/A
Market Cap
£52.51 million
Optionable
Not Optionable
Beta
-0.53
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Ms. Lisa Mary Whewell Anson (Age 56)
    CEO & Executive Director
    Comp: $608.13k
  • Mr. Peter J. Collum
    Chief Financial Officer
  • Dr. James Mead (Age 46)
    Chief Operating Officer
    Comp: $132.67k
  • Dr. Richard Armer
    Chief Scientific Officer
  • Dr. Karl Hard Ph.D. (Age 62)
    Head of Investor Relations
  • Ms. Claire Penelope Solk
    General Counsel & Company Secretary
  • Ms. Caitlin Pearson
    Head of Communications
  • Dr. Cliff Jones
    Senior Vice President of Chemistry, DMPK & Intellectual Property
  • Dr. Caroline Phillips
    Senior Vice President of Biology
  • Mr. Craig Tilston
    Head of Development Operations

REDX Stock Analysis - Frequently Asked Questions

How have REDX shares performed in 2024?

Redx Pharma's stock was trading at GBX 22 at the start of the year. Since then, REDX shares have decreased by 38.6% and is now trading at GBX 13.50.
View the best growth stocks for 2024 here
.

How were Redx Pharma's earnings last quarter?

Redx Pharma Plc (LON:REDX) issued its quarterly earnings data on Monday, November, 19th. The company reported ($7.00) EPS for the quarter, missing the consensus estimate of ($6.50) by $0.50.

What other stocks do shareholders of Redx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Redx Pharma investors own include Digital Globe Services (DGS), OptiBiotix Health (OPTI), TLA Worldwide (TLA), Be Heard Group plc (BHRD.L) (BHRD), Salesforce (CRM), Carnival Co. & (CCL), Burberry Group (BRBY), boohoo group (BOO) and Bank of New York Mellon (BK).

How do I buy shares of Redx Pharma?

Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:REDX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners